Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in HER3 expression profiles between primary and recurrent gynecological cancers.
Kojima Y, Sudo K, Yoshida H, Yazaki S, Tokura M, Mizoguchi C, Okuma HS, Kita S, Yamamoto K, Nishikawa T, Noguchi E, Shimoi T, Tanase Y, Uno M, Ishikawa M, Kato T, Koyama K, Kobayashi M, Kakegawa T, Fujiwara Y, Yonemori K. Kojima Y, et al. Among authors: koyama k. Cancer Cell Int. 2023 Feb 3;23(1):18. doi: 10.1186/s12935-022-02844-z. Cancer Cell Int. 2023. PMID: 36737733 Free PMC article.
Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis.
Inaki K, Shibutani T, Maeda N, Eppenberger-Castori S, Nicolet S, Kaneda Y, Koyama K, Qiu Y, Wakita K, Murakami M. Inaki K, et al. Among authors: koyama k. PLoS One. 2022 Sep 22;17(9):e0274140. doi: 10.1371/journal.pone.0274140. eCollection 2022. PLoS One. 2022. PMID: 36137139 Free PMC article.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: koyama k. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, Abe M, Kaneda Y, Maeda N, Shiose Y, Iguchi T, Ishizaka T, Karibe T, Hayakawa I, Morita K, Nakada T, Nomura T, Wakita K, Kagari T, Abe Y, Murakami M, Ueno S, Agatsuma T. Hashimoto Y, et al. Among authors: koyama k. Clin Cancer Res. 2019 Dec 1;25(23):7151-7161. doi: 10.1158/1078-0432.CCR-19-1745. Epub 2019 Aug 30. Clin Cancer Res. 2019. PMID: 31471314
1,746 results